M&A Deal Summary

Ariceum Acquires Theragnostics

On June 1, 2023, Ariceum acquired life science company Theragnostics for 44M USD

Acquisition Highlights
  • This is Ariceum’s 1st transaction in the Life Science sector.
  • This is Ariceum’s largest (disclosed) transaction.
  • This is Ariceum’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2023-06-01
Target Theragnostics
Sector Life Science
Buyer(s) Ariceum
Deal Type Add-on Acquisition
Deal Value 44M USD

Target

Theragnostics

Bracknell, United Kingdom
Theragnostics is a biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours. Theragnostics was founded in 2015 and is based in Bracknell, England.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ariceum

Berlin, Germany
Category Company
Founded 2021
Sector Life Science
DESCRIPTION

Ariceum is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum was founded in 2021 and is based in Berlin, Germany.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal